Anwaruddin Mohammad

Mr. Anwaruddin Mohammad

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
SDSudhisha Dubey
Sudhisha Dubey
SISusan Idicula-Thomas
Susan Idicula-Thomas
AMAnwaruddin Mohammad
Anwaruddin Mohammad
CSChinnaraj Saravanan
Chinnaraj Saravanan
RVR Raveendra Varma
R Raveendra Varma
AMAnurupa Maitra
Anurupa Maitra
Steroid 21-hydroxylase deficiency is the most common cause of congenital adrenal hyperplasia (CAH). Detection of underlying mutations in CYP21A2 gene encoding steroid 21-hydroxylase enzyme is helpful both for confirmation of diagnosis and management of CAH patients. Here we report a novel 9-bp insertion in CYP21A2 gene and its structural and functional consequences on P450c21 protein by molecular modeling and molecular dynamics simulations methods.

11 February 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
MMMitchell T. McGinty
Mitchell T. McGinty
APAudrey M. Putelo
Audrey M. Putelo
SKSree H. Kolli
Sree H. Kolli
TFTzu-Yu Feng
Tzu-Yu Feng
MDMadison R. Dietl
Madison R. Dietl
MRMelanie Rutkowski
Melanie Rutkowski
Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system. Patients who have ovarian tumors infiltrated with high frequencies of T cells are associated with a greater survival probability. However, therapies to revitalize tumor-associated T cells, such as PD-L1/PD-1 or CTLA4 blockade, are ineffective for the treatment of ovarian cancer. In this study, we demonstrate that for ovarian cancer, Toll-like receptor 5 (TLR5) signaling, for which the only known ligand is bacterial flagellin, governed failure of PD-L1 and CTLA4 blockade. Mechanistically, chronic TLR5 signaling on CD11c+ cells in vivo and in vitro impaired the differentiation of functional IL-12–producing XCR1+CD103+ conventional type 1 dendritic cells, biasing CD11c+ precursor cells toward myeloid subsets expressing high levels of PD-L1. This culminated in impaired activation of CD8+ T cells, reducing CD8+ T-cell function and ability to persist within the ovarian tumor microenvironment. Expansion of XCR1+CD103+ conventional type 1 dendritic cells in situ using Flt3L-Ig in combination with PD-L1 blockade achieved significant survival benefit in TLR5 knockout mice bearing ovarian tumors, whereas no benefit was observed in the presence of TLR5 signaling. Thus, we have identified a host-intrinsic mechanism leading to the failure of PD-L1 blockade for ovarian cancer, demonstrating that chronic TLR5 signaling on CD11c+ cells is a barrier limiting the efficacy of checkpoint therapy.

17 June 2026
Verified
Other
Open access
MMMitchell T. McGinty
Mitchell T. McGinty
APAudrey M. Putelo
Audrey M. Putelo
SKSree H. Kolli
Sree H. Kolli
TFTzu-Yu Feng
Tzu-Yu Feng
MDMadison R. Dietl
Madison R. Dietl
MRMelanie Rutkowski
Melanie Rutkowski
Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system. Patients who have ovarian tumors infiltrated with high frequencies of T cells are associated with a greater survival probability. However, therapies to revitalize tumor-associated T cells, such as PD-L1/PD-1 or CTLA4 blockade, are ineffective for the treatment of ovarian cancer. In this study, we demonstrate that for ovarian cancer, Toll-like receptor 5 (TLR5) signaling, for which the only known ligand is bacterial flagellin, governed failure of PD-L1 and CTLA4 blockade. Mechanistically, chronic TLR5 signaling on CD11c+ cells in vivo and in vitro impaired the differentiation of functional IL-12–producing XCR1+CD103+ conventional type 1 dendritic cells, biasing CD11c+ precursor cells toward myeloid subsets expressing high levels of PD-L1. This culminated in impaired activation of CD8+ T cells, reducing CD8+ T-cell function and ability to persist within the ovarian tumor microenvironment. Expansion of XCR1+CD103+ conventional type 1 dendritic cells in situ using Flt3L-Ig in combination with PD-L1 blockade achieved significant survival benefit in TLR5 knockout mice bearing ovarian tumors, whereas no benefit was observed in the presence of TLR5 signaling. Thus, we have identified a host-intrinsic mechanism leading to the failure of PD-L1 blockade for ovarian cancer, demonstrating that chronic TLR5 signaling on CD11c+ cells is a barrier limiting the efficacy of checkpoint therapy.

2 May 2025
Verified
Other
Open access
PDF file
MMMitchell T. McGinty
Mitchell T. McGinty
APAudrey M. Putelo
Audrey M. Putelo
SKSree H. Kolli
Sree H. Kolli
TFTzu-Yu Feng
Tzu-Yu Feng
MDMadison R. Dietl
Madison R. Dietl
MRMelanie Rutkowski
Melanie Rutkowski
Figure S6. Assessment of temporal changes in CD4 and CD8 T cells from the ovarian tumor microenvironment and tumor-draining lymph node in wild type and TLR5 KO ovarian tumor bearing mice.

2 May 2025
Verified
Other
Open access
PDF file
MMMitchell T. McGinty
Mitchell T. McGinty
APAudrey M. Putelo
Audrey M. Putelo
SKSree H. Kolli
Sree H. Kolli
TFTzu-Yu Feng
Tzu-Yu Feng
MDMadison R. Dietl
Madison R. Dietl
MRMelanie Rutkowski
Melanie Rutkowski
Figure S5. CITE-seq from FLT3L expanded bone marrow with or without chronic flagellin stimulation.

2 May 2025
Verified
Other
Open access
MMMitchell T. McGinty
Mitchell T. McGinty
APAudrey M. Putelo
Audrey M. Putelo
SKSree H. Kolli
Sree H. Kolli
TFTzu-Yu Feng
Tzu-Yu Feng
MDMadison R. Dietl
Madison R. Dietl
MRMelanie Rutkowski
Melanie Rutkowski
Supplementary Table S1 from TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer